REGENXBIO bets that gene therapy is finally ready to move from the lab to real-world patients, with several treatments nearing launch and a manufacturing setup that could improve profits as it scales. The big question is whether those launches and possible licensing deals arrive fast enough to outrun high spending, regulators, and well-funded rivals.Read more
Gene therapy demand is rising, but REGENXBIO’s path depends heavily on a small number of late-stage treatments that could run into approval and insurance hurdles. It also needs steady funding to keep moving, and tougher competition could make it harder to turn future launches into lasting profits.Read more
REGENXBIO aims to turn its gene therapy research into real products, helped by late-stage study results, potential approvals, and backing from large drug partners. The upside is big if its next treatments work and get covered by insurers, but setbacks in testing, safety concerns, or partner and pricing issues could quickly derail the story.Read more
No trending discussion available.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
